logo
Plus   Neg
Share
Email

Carnival Cuts 2019 Profit View; Stock Down

Carnival Corporation & plc (CCL,CUK,CCL.L) said it cut its adjusted earnings per share outlook for full year 2019 to a range of $4.23 to $4.27, from the prior range of $4.25 to $4.35 per share, reflecting recent fuel price increases. Analysts polled by Thomson Reuters expect the company to report earnings of $4.33 per share for fiscal year 2019. Analysts' estimates typically exclude special items.

CCL is currently trading at $43.97, down $4.09 or 8.51 percent.

The company expects full year 2019 constant currency net cruise revenues to be up approximately 4.0 percent, with capacity growth of 4.2 percent.

The company expects adjusted earnings per share for the fourth quarter 2019 to be in the range of $0.46 to $0.50 versus 2018 adjusted earnings per share of $0.70. Analysts expect earnings of $0.64 per share for the fourth-quarter. Fourth quarter constant currency net revenue yields are expected to be down 2.0 to 3.0 percent compared to the prior year.

For full year 2020, the company expects capacity growth of approximately 7 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amity Packing Company Inc. is recalling around 2,020 pounds of raw ground beef products for possible plastic presence, the U.S. Department of Agriculture's Food Safety and Inspection Service stated. The agency said the products may be contaminated with extraneous materials, specifically clear, thin pliable plastic. The recall was initiated after Pre Brands LLC received two consumer complaints. Golden Pearl Trading Corp. is recalling certain ready-to-eat or RTE imported Siluriformes products that were produced without benefit of import inspection, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves around 12,054 pounds of Siluriformes products that were not presented for import re-inspection into the United States. The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft...
RELATED NEWS
Follow RTT
>